ArticleMedical oncology (Northwood, London, England)2021
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer.International journal of clinical oncology · 2026Article
- Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology.Cancer medicine · 2026Article
- Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities.Therapeutic advances in medical oncology · 2026Article
- Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.Scientific reports · 2025Article
- Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer.Cancer research and treatment · 2025Article
- A case of primary ovarian clear cell carcinoma withInternational cancer conference journal · 2025Article
- Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification.BJC reports · 2025Article
- Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.British journal of cancer · 2025Article
- Cadonilimab combined with trastuzumab and chemotherapy for HER2-positive gastric cancer with bone marrow metastasis and DIC: a case report and literature review.Frontiers in immunology · 2025Review
- Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma.Scientific reports · 2024Article
- Molecular characteristics of gastric cancer withHeliyon · 2023Article
- Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.Cancer medicine · 2023Article
- PD-L1 gene amplification and focality: relationship with protein expression.Journal for immunotherapy of cancer · 2023Article
- Clinicopathological features and differential diagnosis of gastric pleomorphic giant cell carcinoma.Open life sciences · 2023Article
- An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.Frontiers in oncology · 2023Article
- Squamous cell carcinoma of the prostate withIJU case reports · 2022Article
- Angiopoietin-like 4 promotes glucose metabolism by regulating glucose transporter expression in colorectal cancer.Journal of cancer research and clinical oncology · 2022Article
- RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Next-generation sequencing, should I use anti-HER2 therapy forTherapeutic advances in medical oncology · 2022Article
- Impact of p53 mutations on the synergistic effects of metformin and radiation on colorectal cancer cells.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
Assessing Erb-b2 receptor tyrosine kinase 2 (ERBB2) amplification status in breast and gastric cancer is necessary for deciding the best therapeutic strategy. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are currently used for assessing protein levels and gene copy number (CN), respectively. The use of next-generation sequencing (NGS) to measure ERBB2 CN in breast cancer is approved by the United States Federal Drug Administration as a companion diagnostic. However, a CN of less than 8 is evaluated as "equivocal", which means that some ERBB2 amplification cases diagnosed as "HER2 negative" might be false-negative cases. We reviewed the results of gene profiling targeting 160 cancer-related genes in breast (N = 90) and non-breast (N = 19) cancer tissue, and compared the ERBB2 CN results with the IHC/FISH scores. We obtained an estimated CN from the measured CN by factoring in the histological proportion of tumor cells and found that an ERBB2-estimated CN of 3.2 or higher was concordant with the combined IHC/FISH outcome in 98.4% (88/90) of breast cancer cases, while this was not always evident among non-breast cancer cases. Therefore, NGS-estimated ERBB2 CN could be considered a diagnostic test for anti-HER2 therapy after the completion of adequate prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.